vs
Axos Financial, Inc.（AX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Axos Financial, Inc.的2.0倍（$772.1M vs $392.2M），Axos Financial, Inc.净利率更高（31.8% vs 12.7%，领先19.0%），过去两年Axos Financial, Inc.的营收复合增速更高（16.1% vs 9.0%）
Axos Financial是总部位于美国内华达州拉斯维加斯的银行控股公司，旗下拥有直销银行Axos Bank，同时提供注册投资顾问服务及电子交易平台，深耕数字化金融赛道，可为用户提供多元便捷的金融服务解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$392.2M
净利率更高
AX
高出19.0%
12.7%
两年增速更快
AX
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $392.2M | $772.1M |
| 净利润 | $124.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 31.8% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | 18.5% | 3.9% |
| 每股收益（稀释后） | $2.15 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRVTY
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $772.1M | ||
| Q3 25 | $323.4M | $698.9M | ||
| Q2 25 | $321.4M | $720.3M | ||
| Q1 25 | $308.8M | $664.8M | ||
| Q4 24 | $307.9M | $729.4M | ||
| Q3 24 | $320.7M | $684.0M | ||
| Q2 24 | $290.9M | $691.7M |
净利润AXRVTY
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $98.4M | ||
| Q3 25 | $112.4M | $46.7M | ||
| Q2 25 | $110.7M | $53.9M | ||
| Q1 25 | $105.2M | $42.2M | ||
| Q4 24 | $104.7M | $94.6M | ||
| Q3 24 | $112.3M | $94.4M | ||
| Q2 24 | $104.9M | $55.4M |
毛利率AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 14.5% | ||
| Q3 25 | 46.3% | 11.7% | ||
| Q2 25 | 48.5% | 12.6% | ||
| Q1 25 | 47.9% | 10.9% | ||
| Q4 24 | 48.8% | 16.3% | ||
| Q3 24 | 49.6% | 14.3% | ||
| Q2 24 | 49.6% | 12.4% |
净利率AXRVTY
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 12.7% | ||
| Q3 25 | 34.7% | 6.7% | ||
| Q2 25 | 34.4% | 7.5% | ||
| Q1 25 | 34.1% | 6.4% | ||
| Q4 24 | 34.0% | 13.0% | ||
| Q3 24 | 35.0% | 13.8% | ||
| Q2 24 | 36.0% | 8.0% |
每股收益（稀释后）AXRVTY
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $0.86 | ||
| Q3 25 | $1.94 | $0.40 | ||
| Q2 25 | $1.89 | $0.46 | ||
| Q1 25 | $1.81 | $0.35 | ||
| Q4 24 | $1.80 | $0.77 | ||
| Q3 24 | $1.93 | $0.77 | ||
| Q2 24 | $1.75 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.1B | $7.3B |
| 总资产 | $29.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $919.9M | ||
| Q3 25 | $2.6B | $931.4M | ||
| Q2 25 | $1.9B | $991.8M | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $2.6B | $1.2B | ||
| Q2 24 | $2.0B | $2.0B |
总债务AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $312.7M | — | ||
| Q1 25 | $377.4M | — | ||
| Q4 24 | $358.7M | — | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
股东权益AXRVTY
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $7.3B | ||
| Q3 25 | $2.8B | $7.4B | ||
| Q2 25 | $2.7B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.5B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B |
总资产AXRVTY
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $12.2B | ||
| Q3 25 | $27.4B | $12.1B | ||
| Q2 25 | $24.8B | $12.4B | ||
| Q1 25 | $24.0B | $12.4B | ||
| Q4 24 | $23.7B | $12.4B | ||
| Q3 24 | $23.6B | $12.8B | ||
| Q2 24 | $22.9B | $13.4B |
负债/权益比AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $182.0M | ||
| Q3 25 | $118.4M | $138.5M | ||
| Q2 25 | $490.3M | $134.3M | ||
| Q1 25 | $73.7M | $128.2M | ||
| Q4 24 | $162.5M | $174.2M | ||
| Q3 24 | $70.8M | $147.9M | ||
| Q2 24 | $305.5M | $158.6M |
自由现金流AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $161.8M | ||
| Q3 25 | $109.3M | $120.0M | ||
| Q2 25 | $436.1M | $115.5M | ||
| Q1 25 | $65.1M | $112.2M | ||
| Q4 24 | $156.4M | $149.8M | ||
| Q3 24 | $53.0M | $125.6M | ||
| Q2 24 | $269.5M | $136.6M |
自由现金流率AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | 21.0% | ||
| Q3 25 | 33.8% | 17.2% | ||
| Q2 25 | 135.7% | 16.0% | ||
| Q1 25 | 21.1% | 16.9% | ||
| Q4 24 | 50.8% | 20.5% | ||
| Q3 24 | 16.5% | 18.4% | ||
| Q2 24 | 92.6% | 19.7% |
资本支出强度AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 16.9% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 5.5% | 3.3% | ||
| Q2 24 | 12.4% | 3.2% |
现金转化率AXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | 1.85× | ||
| Q3 25 | 1.05× | 2.97× | ||
| Q2 25 | 4.43× | 2.49× | ||
| Q1 25 | 0.70× | 3.03× | ||
| Q4 24 | 1.55× | 1.84× | ||
| Q3 24 | 0.63× | 1.57× | ||
| Q2 24 | 2.91× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
